Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06409026 · ClinicalTrials.gov registry record · Phase 4
Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension
A Phase 4 study of Pulmonary Arterial Hypertension, sponsored by Mayo Clinic.
- Active
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06409026 is a Phase 4 study of Pulmonary Arterial Hypertension that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 30 participants, below the 462-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06409026, a Phase 4 study of Pulmonary Arterial Hypertension, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see if the drug sotatercept given for 36 weeks improves the functioning of the heart and improves quality of life.
Conditions Studied
Interventions
- DRUG Sotatercept
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-07-05 |
| Est. Completion | 2026-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06409026
The ClinicalTrials.gov registry entry for NCT06409026 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 462-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (94% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Sotatercept is the first listed.
NCT06409026 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT06409026 about?
NCT06409026 is a clinical study titled "Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension". The purpose of this study is to see if the drug sotatercept given for 36 weeks improves the functioning of the heart and improves quality of life.
What is the current status of trial NCT06409026?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2024-07-05. Estimated completion is 2026-03.
What conditions does trial NCT06409026 study?
This clinical trial studies the following conditions: Pulmonary Arterial Hypertension.
What interventions are being tested in trial NCT06409026?
The interventions under investigation include: Sotatercept (DRUG).
Who is sponsoring clinical trial NCT06409026?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06409026 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Arterial Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension
ACTIVE NOT RECRUITING · Phase 4
-
Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
COMPLETED · Phase 4
-
Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication
COMPLETED · Phase 4
-
Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401
COMPLETED · Phase 4
-
Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension
COMPLETED · Phase 4
-
Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.